Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...
Posted by Michael Wonder on 17 Jul 2019
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 16 Jul 2019
Seattle Genetics and Astellas announce submission of biologics license application to FDA for enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer
16 July 2019 - Submission based on pivotal Phase 2 trial results recently presented at Annual Meeting of American Society of ...
Posted by Michael Wonder on 13 Jul 2019
Protecting PHARMAC and cancer treatment
13 July 2019 - The "postcode lottery", delays and other failings for cancer treatment need to be addressed. ...
Posted by Michael Wonder on 13 Jul 2019
Janssen submits application to U.S. FDA seeking approval of new Darzalex (daratumumab) subcutaneous formulation
12 July 2019 - Submission inclusive of data from Phase 3 COLUMBA study presented at ASCO. ...
Posted by Michael Wonder on 12 Jul 2019
Improving affordability of new essential cancer medicines
11 July 2019 - Effective cancer care requires investment in health infrastructure, a trained health workforce, and quality-assured, affordable medicines within ...
Posted by Michael Wonder on 11 Jul 2019
Proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas
11 July 2019 - PHARMAC is seeking feedback on proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma
10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 10 Jul 2019
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
10 July 2019 - The U.S. FDA has accepted for review the biologics license application for isatuximab for the treatment ...
Posted by Michael Wonder on 10 Jul 2019
Cellectar receives FDA fast track designation for CLR 131 in diffuse large B-cell lymphoma
9 July 2019 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in relapsed ...
Posted by Michael Wonder on 09 Jul 2019
FDA accepts Merck’s supplemental biologics license applications for Keytruda (pembrolizumab) six-week dosing schedule for melanoma and multiple other indications
9 July 2019 - Merck today announced that the U.S. FDA has accepted for review six supplemental biologics license applications to ...
Posted by Michael Wonder on 09 Jul 2019
The fragility of phase 3 trials supporting FDA approved anti-cancer medicines: a retrospective analysis
8 July 2019 - The fragility index of trial results—ie, the minimum number of changes from non-events to events resulting in ...
Posted by Michael Wonder on 09 Jul 2019
Breast cancer specialists throw their weight behind long-running fight for increased Government drug funding
9 July 2019 - Several petitions, two marches on Parliament and countless emotive pleas have been fruitless in a long-running ...